Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Int J Oral Maxillofac Surg ; 43(2): 156-62, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24100154

ABSTRACT

A navigation-assisted multidisciplinary network to improve the interface between radiology, surgery, radiotherapy, and pathology in the field of head and neck cancer is described. All implicated fields are integrated by a common server platform and have remote data access in a ready-to-use format. The margins of resection and exact locations of biopsies are mapped intraoperatively. The pathologist uses the numerical coordinates of these samples to precisely trace each specimen in the anatomical field. Subsequently, map-guided radiotherapy is planned. In addition to the benefits of image-guided resection, this model enables radiotherapy planning according to the specific coordinates of the resection defect plus any residually affected sites identified by the pathologist. Irradiation of adjacent healthy structures is thereby minimized. In summary, the navigation-assisted network described grants timely multidisciplinary feedback between all fields involved, attains meticulous pathological definition, and permits optimized coordinate-directed radiotherapy.


Subject(s)
Computer Communication Networks , Diagnostic Imaging , Head and Neck Neoplasms/surgery , Radiotherapy Planning, Computer-Assisted , Surgery, Computer-Assisted , User-Computer Interface , Head and Neck Neoplasms/diagnosis , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/radiotherapy , Humans , Image Processing, Computer-Assisted , Imaging, Three-Dimensional , Software
2.
Br J Cancer ; 94(8): 1099-106, 2006 Apr 24.
Article in English | MEDLINE | ID: mdl-16622435

ABSTRACT

The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled) underwent tumour resection after three 3-week cycles of docetaxel 85 mg m-2 (day 1) plus cisplatin 40 or 50 mg m-2 (days 1 and 2). Therapy was well tolerated (overall grade 3 toxicity occurred in 48% patients; no grade 4 nonhaematological toxicity was reported), with no observed late toxicities. Median overall survival (OS) and event-free survival (EFS) times were 35 and 15 months, respectively, in the 75 patients who underwent surgery; corresponding figures for all 90 patients enrolled were 28 and 12 months. At 3 years after initiating trial therapy, 27 out of 75 patients (36%) were alive and tumour free. At 5-year follow-up, 60 and 65% of patients had local relapse and distant metastases, respectively. The most common sites of distant metastases were the lung (24%) and brain (17%). Factors associated with OS, EFS and risk of local relapse and distant metastases were complete tumour resection and chemotherapy activity (clinical response, pathologic response, mediastinal downstaging). Neoadjuvant docetaxel-cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.


Subject(s)
Carcinoma, Non-Small-Cell Lung/surgery , Lung Neoplasms/surgery , Adult , Aged , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/drug therapy , Chemotherapy, Adjuvant , Cisplatin/therapeutic use , Combined Modality Therapy , Disease-Free Survival , Docetaxel , Female , Follow-Up Studies , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/drug therapy , Male , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Prognosis , Recurrence , Risk Assessment , Survival Rate , Taxoids/therapeutic use , Time Factors , Treatment Outcome
3.
Ann Thorac Surg ; 69(5): 1550-5, 2000 May.
Article in English | MEDLINE | ID: mdl-10881840

ABSTRACT

BACKGROUND: To compare the prognostic relevance of Masaoka and Müller-Hermelink classifications. METHODS: We treated 71 patients with thymic tumors at our institution between 1980 and 1997. Complete follow-up was achieved in 69 patients (97%) with a mean follow up-time of 8.3 years (range, 9 months to 17 years). RESULTS: Masaoka stage I was found in 31 patients (44.9%), stage II in 17 (24.6%), stage III in 19 (27.6%), and stage IV in 2 (2.9%). The 10-year overall survival rate was 83.5% for stage I, 100% for stage IIa, 58% for stage IIb, 44% for stage III, and 0% for stage IV. The disease-free survival rates were 100%, 70%, 40%, 38%, and 0%, respectively. Histologic classification according to Müller-Hermelink found medullary tumors in 7 patients (10.1%), mixed in 18 (26.1%), organoid in 14 (20.3%), cortical in 11 (15.9%), well-differentiated thymic carcinoma in 14 (20.3%), and endocrine carcinoma in 5 (7.3%), with 10-year overall survival rates of 100%, 75%, 92%, 87.5%, 30%, and 0%, respectively, and 10-year disease-free survival rates of 100%, 100%, 77%, 75%, 37%, and 0%, respectively. Medullary, mixed, and well-differentiated organoid tumors were correlated with stage I and II, and well-differentiated thymic carcinoma and endocrine carcinoma with stage III and IV (p < 0.001). Multivariate analysis showed age, gender, myasthenia gravis, and postoperative adjuvant therapy not to be significant predictors of overall and disease-free survival after complete resection, whereas the Müller-Hermelink and Masaoka classifications were independent significant predictors for overall (p < 0.05) and disease-free survival (p < 0.004; p < 0.0001). CONCLUSIONS: The consideration of staging and histology in thymic tumors has the potential to improve recurrence prediction and patient selection for combined treatment modalities.


Subject(s)
Thymoma/classification , Thymoma/mortality , Thymus Neoplasms/classification , Thymus Neoplasms/mortality , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Female , Humans , Male , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local , Prognosis , Thymoma/pathology , Thymoma/surgery , Thymus Neoplasms/pathology , Thymus Neoplasms/surgery
4.
Ann Oncol ; 10(6): 677-83, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10442190

ABSTRACT

BACKGROUND: The upper limit of the natural decline in creatinine clearance is 1 ml/min/year. To define the loss of renal function, we started a long-term assessment of patients with ovarian cancer treated by whole abdominal irradiation (WAI) with preceding cisplatin chemotherapy (CDDP) and second-look laparotomy (SLL). PATIENTS AND METHODS: We analyzed the creatinine clearance over time of 56 patients treated from 1982 to 1988 for ovarian cancer. Thirty-one of 56 patients had received WAI after their initial surgery, and 25 of 56 patients had undergone CDDP therapy followed by SLL, and then WAI after their initial surgery. Median follow-up was 99 months (7-156). Twenty of 56 patients accepted our invitation for additional assessment of tubular function, nine of the 31 patients without CDDP therapy and SLL, and 11 of the 25 patients with CDDP followed by SLL and WAI. Ten of twenty patients had received four to six cycles CDDP, 80 mg/m2/cycle, and one patient nine cycles. The median total dose for each kidney was 1450 cGy (480-1690). RESULTS: The mean creatinine clearance decreased from 84 ml/min to 66 ml/min. Seventy-six percent of the 25 patients who had undergone CDDP therapy, SLL and WAI had declines of more than 1 ml/min/year, 64% of these patients of more than 2 ml/min/year. For the 31 patients who had received WAI after their initial surgery, the corresponding numbers were 71% and 55%, respectively. The tubular function of the 20 patients who had undergone the additional investigations was not impaired. CONCLUSION: The decline in renal function after WAI is more pronounced than in healthy subjects. The treatment with cisplatin and SLL prior to WAI does not seem to contribute to this loss of kidney function.


Subject(s)
Antineoplastic Agents/therapeutic use , Cisplatin/therapeutic use , Kidney/physiopathology , Ovarian Neoplasms/radiotherapy , Radiotherapy/adverse effects , Abdomen/radiation effects , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Cisplatin/administration & dosage , Combined Modality Therapy , Creatinine/metabolism , Female , Follow-Up Studies , Glomerular Filtration Rate , Humans , Kidney/radiation effects , Middle Aged , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/physiopathology
5.
Ther Umsch ; 55(7): 394-8, 1998 Jul.
Article in German | MEDLINE | ID: mdl-9702101

ABSTRACT

Surgical progresses in the treatment of lung cancer are not only related to technical details of surgery itself, but rely much upon an interdisciplinary approach before and after the operation. This will improve patient selection, multimodality treatment concepts and morbidity and mortality with overall improvement of quality of life in these patients.


Subject(s)
Carcinoma, Bronchogenic/surgery , Lung Neoplasms/surgery , Patient Care Team , Carcinoma, Bronchogenic/mortality , Carcinoma, Bronchogenic/pathology , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Carcinoma, Small Cell/mortality , Carcinoma, Small Cell/pathology , Carcinoma, Small Cell/surgery , Combined Modality Therapy , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lung Neoplasms/secondary , Neoplasm Staging , Prognosis , Survival Rate
6.
Ther Umsch ; 55(7): 399-401, 1998 Jul.
Article in German | MEDLINE | ID: mdl-9702102

ABSTRACT

Although surgeons are able to resect completely locally advanced non-small cell lung cancer with mediastinal lymph node involvement (stage IIIA), the majority of patients succumb from metastatic disease. Therefore, neoadjuvant therapy was introduced in the management of this disease in order to eradicate distant metastases at an early stage. Phase II trials with preoperative chemotherapy in stage IIIA patients have shown that the pathological response (amount of tumour necrosis) and the clearance of mediastinal lymph node correlate with a better survival and is the best predictor for eradication of distant metastases. Indeed, three small randomised phase III studies have demonstrated a survival advantage for preoperative chemotherapy compared to surgery alone. Further studies are required to determine the best neoadjuvant regimen inducing the largest amount of tumour necrosis.


Subject(s)
Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Chemotherapy, Adjuvant , Clinical Trials as Topic , Combined Modality Therapy , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Neoplasm Staging , Survival Rate
7.
Ther Umsch ; 55(7): 402-4, 1998 Jul.
Article in German | MEDLINE | ID: mdl-9702103

ABSTRACT

Radiation is a standard treatment for patients with locally advanced non-small cell lung cancer. Only 5% of patients are alive after 5 years. Improvement of local control and survival time have been yielded using knowledge in radiobiology and technical innovations, especially three dimensional planning on the basis of CT and MRI. Further improvement could be reached by performing combination of radio- and chemotherapy. However, the best sequence of chemo- and radiotherapy could not be defined yet.


Subject(s)
Carcinoma, Bronchogenic/radiotherapy , Carcinoma, Non-Small-Cell Lung/radiotherapy , Lung Neoplasms/radiotherapy , Carcinoma, Bronchogenic/drug therapy , Carcinoma, Bronchogenic/mortality , Carcinoma, Bronchogenic/pathology , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Chemotherapy, Adjuvant , Combined Modality Therapy , Follow-Up Studies , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Survival Rate
8.
Strahlenther Onkol ; 174(6): 306-10, 1998 Jun.
Article in German | MEDLINE | ID: mdl-9645211

ABSTRACT

BACKGROUND: Patients with carcinomas of the upper aero-digestive tract often suffer from ear pain as a tumor associated syndrome. This prospective study examines the predictive and prognostic value of this symptom. PATIENTS AND METHODS: Ninety-six consecutive patients who completed a locally radiotherapy of a carcinoma of the oropharynx were prospectively evaluated and followed. Forty-nine out of 96 patients stated the symptom, either spontaneously or after questioning. The 2 groups showed no difference regarding TNM-classification, histology and total dose. Overall survival, local control and disease specific survival were calculated according to Kaplan-Meier and compared by the log-rank test. RESULTS: A clinically complete remission was obtained in significantly fewer patients with reflex-otalgia as compared to patients without reflex-otalgia, 61.2% versus 89.3%, p < 0.002. Local control of patients with reflex-otalgia was significantly less with 49%, mean follow-up 564 days, in comparison to local control in patients without reflex-otalgia, mean follow-up 613 days, p = 0.01. Disease specific survival was significantly worse for patients with reflex-otalgia, p < 0.012. The probability of local control of T1/T2 tumors with reflex-otalgia was similar to T3/T4 tumors without reflex-otalgia. Local control for all tumor categories combined is 74% for patients without reflex-otalgia versus 49% for patients with reflex-otalgia. CONCLUSION: In our patients, reflex-otalgia is a new and statistically significant parameter for the probability of local control and disease specific survival.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Earache/radiotherapy , Oropharyngeal Neoplasms/radiotherapy , Paraneoplastic Syndromes/radiotherapy , Reflex, Abnormal/radiation effects , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Earache/mortality , Earache/pathology , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging , Oropharyngeal Neoplasms/mortality , Oropharyngeal Neoplasms/pathology , Paraneoplastic Syndromes/mortality , Paraneoplastic Syndromes/pathology , Prognosis , Prospective Studies , Radiotherapy, High-Energy , Survival Analysis
9.
Br J Dermatol ; 134(4): 763-5, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8733388

ABSTRACT

Classic angiosarcoma is an uncommon malignant neoplasm of vascular differentiation which is highly aggressive. The diagnosis is often delayed and, since the response to treatment mainly depends on the size of the tumour, the prognosis is usually poor. Here we report a 76-year-old man in whom an extensive angiosarcoma of the scalp was treated by excision followed by wide-field radiotherapy. More than 4 years later there are no signs of local recurrence or of metastasis.


Subject(s)
Hemangiosarcoma/radiotherapy , Hemangiosarcoma/surgery , Scalp , Skin Neoplasms/radiotherapy , Skin Neoplasms/surgery , Aged , Combined Modality Therapy , Hemangiosarcoma/pathology , Humans , Male , Skin Neoplasms/pathology , Treatment Outcome
10.
Ther Umsch ; 51(4): 272-7, 1994 Apr.
Article in German | MEDLINE | ID: mdl-7514815

ABSTRACT

Inoperable pulmonary malignancies can present with local stenoses of the central airways either at the time of diagnosis or later on. Depending on their localization, these obstructions cause progressive dyspnea, postobstructive atelectasis and/or pneumonia. The patient's general condition will deteriorate, and at the tracheal level life-threatening dyspnea can develop. If central airways stenosis is suspected, fiberbronchoscopy is mandatory to decide whether local endobronchial palliation is a feasible treatment modality. Usually, local palliation is combined with chemo-and/or radiotherapy. Laser resection using the Nd-YAG laser is performed for obstructions caused by endoluminal tumour growth and leads to an immediate effect after a single session. Brachytherapy means local, endobronchial irradiation with a short depth of penetration. The active probe is placed with the aid of the fiberbronchoscope. Brachytherapy can be used alone, but is often combined with an initial laser resection for the consolidation of the treatment effect. The principal of photodynamic therapy consists of photosensitization of tumour cells followed by local laser light application which leads to cell death. In selected cases this treatment can be curative. Extrinsic stenoses which are caused by external compression of the airways or by thickening of the airway walls through submucosal tumour spread must be treated by dilatation and insertion of stents (endoprostheses) to maintain airway patency. These stents--mostly self-expanding silicone or metal devices--are usually inserted with the rigid bronchoscope. Again, endobronchial and/or percutaneous radiotherapy is added to obtain longer local tumour control.


Subject(s)
Lung Neoplasms/radiotherapy , Palliative Care/methods , Airway Obstruction/etiology , Airway Obstruction/therapy , Brachytherapy , Bronchoscopy , Humans , Laser Therapy , Lung Neoplasms/complications , Lung Neoplasms/surgery , Photochemotherapy/methods , Stents
SELECTION OF CITATIONS
SEARCH DETAIL
...